Coronavirus News Roundup: Johnson & Johnson’s Vaccine Enters Phase 3 Trial, FDA Authorizes Point-of-Care Antibody Test

Article

Here's this week's roundup of the coronavirus-related news you should know.

COVID-19

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), has infected an estimated 32,345,456 individuals worldwide, and approximately 6.9 million Americans. The latest COVID-19 related news includes promising phase 3 clinical trials, as well as the FDA’s authorization of the first serology point-of-care (POC) COVID-19 test.

Here’s a roundup of the latest coronavirus-related news:

Phase 3 EMPACTA Study: Tocilizumab Shows Efficacy in COVID-19 Associated Pneumonia

Treatment with tocilizumab (Actemra; Genentech) reduced the likelihood of needing mechanical ventilation in hospitalized patients with COVID-19 associated pneumonia, according to results from a phase 3 study.

Read more

Walmart Pilots Drone Delivery of COVID-19 Tests

Walmart is piloting drone delivery of at-home COVID-19 self-collection kits, which provides a contactless testing option amid the pandemic, the retailer said.

Read more

FDA Issues EUA for First Point-of-Care COVID-19 Antibody Test

The FDA has issued an emergency use authorization (EUA) for the first serology (antibody) POC test for COVID-19.

Read more

Johnson & Johnson’s COVID-19 Vaccine Candidate Enters Phase 3 Trial

Johnson & Johnson announced the initiation of its phase 3 clinical trial for Janssen’s COVID-19 vaccine candidate, JNJ-78436735, according to a press release.

Read more

Study Compares Clinical Features of COVID-19 and Seasonal Influenza

The United States is still in the midst of the COVID-19 pandemic and the 2020-2021 influenza season is on the way.

How much the upcoming season will tax a health care system that has been stretched is unknown. However, a new report in JAMA Network Open offers a look at the similarities and differences between COVID-19 and seasonal influenza.

Read more

Study Evaluates Famotidine Use in Hospitalized COVID-19

Results from a recent study showed that famotidine was associated with a reduced risk of clinical deterioration leading to intubation or death in patients hospitalized with SARS-CoV-2, the virus that causes COVID-19.

Read more

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.